肝脏UGT2B介导的清除促进了高脂肪饮食诱导的MASLD中的脂质积累
Liping Zhou1, Yingzhuan Zheng2, Yujie Qiao1
1Obesity and Metabolic Diseases Research Center, Department of Medical Laboratory Technology, School of Basic Medical Sciences, Chongqing Medical University, Chongqing 400016, China.
在男性中,与代谢功能障碍相关的脂肪性肝病 (MASLD) 涉及肝脏胆固醇和的改变. 提高UGT2B酶的调节加快了的分解,解释了低水平,并建议UGT2B作为治疗标.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 内分泌学 在内分泌学.
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 与代谢功能障碍相关的脂肪性肝病 (MASLD) 与男性的低丸激素有关.
- 在MASLD中,肝脏胆固醇代谢发生变化,但其与的联系仍然不清楚.
研究的目的:
- 为了研究肝脏胆固醇生物合成,代谢和MASLD病变之间的相互作用.
- 阐明尿素二酸盐-葡萄糖转移酶家族2成员B (UGT2B) 酶在MASLD相关的变化中的作用.
主要方法:
- 建立了一个高脂肪饮食 (HFD) 诱导的MASLD小鼠模型.
- 使用转录组学,代谢组学,ELISA,西部抹杀和qPCR进行综合分析.
- 用肝细胞,油酸,和UGT2B抑制剂进行了体外实验.
主要成果:
- HFD增加了肝脏胆固醇,并激活了胆固醇合成和代谢途径.
- UGT2B酶和基碳化合物受体 (AHR) 的上调;血液丸激素最初上升,然后下降.
- 在体外,UGT2B抑制恢复了丸激素对脂质积累的保护作用.
结论:
- 在MASLD中,HFD诱导了动态的,UGT2B介导的肝体代谢.
- 早期的补偿性丸激素增加被增强的UGT2B清除所否定,导致消耗.
- 准肝脏UGT2B酶为MASLD提供了一个潜在的治疗策略.
更多相关视频
09:15Vinyl Chloride and High-Fat Diet as a Model of Environment and Obesity Interaction
Published on: January 12, 2020
13:09Rapid Model to Evaluate the Anti-Obesity Potential of a Combination of Syzygium aromaticum Clove and Cuminun cyminum Cumin on C57BL6/j Mice Fed High-Fat Diet
Published on: July 31, 2021
相关概念视频
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
A recent model describes pravastatin's hepatobiliary excretion,...
Hepatic Drug Clearance: Restrictive and Nonrestrictive Clearance
Most drugs undergo restrictive clearance, which is proportional to the...
Hepatic Drug Clearance: Role of Transporters
Hepatic Drug Clearance: Effect of Protein Binding
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
What are Lipids?
Lipid Digestion
